Cerus Corporation (CERS)
NASDAQ: CERS · Real-Time Price · USD
1.760
0.00 (0.00%)
At close: Nov 28, 2025, 1:00 PM EST
1.790
+0.030 (1.70%)
After-hours: Nov 28, 2025, 4:05 PM EST
Cerus Revenue
Cerus had revenue of $52.70M in the quarter ending September 30, 2025, with 14.52% growth. This brings the company's revenue in the last twelve months to $199.19M, up 13.03% year-over-year. In the year 2024, Cerus had annual revenue of $180.27M with 15.29% growth.
Revenue (ttm)
$199.19M
Revenue Growth
+13.03%
P/S Ratio
1.67
Revenue / Employee
$316,176
Employees
630
Market Cap
338.07M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 180.27M | 23.90M | 15.29% |
| Dec 31, 2023 | 156.37M | -5.68M | -3.51% |
| Dec 31, 2022 | 162.05M | 31.19M | 23.83% |
| Dec 31, 2021 | 130.86M | 38.94M | 42.36% |
| Dec 31, 2020 | 91.92M | 17.27M | 23.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CERS News
- 5 days ago - Cerus: IFC Growth And RBC Optionality - Seeking Alpha
- 22 days ago - Cerus Corporation (CERS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance - Business Wire
- 5 weeks ago - Cerus Corporation Announces Abstracts and Industry Workshop on IFC at the 2025 AABB Annual Meeting - Business Wire
- 6 weeks ago - Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire
- 3 months ago - The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions - Business Wire
- 3 months ago - Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025 - Business Wire
- 4 months ago - Cerus Corporation (CERS) Q2 2025 Earnings Call Transcript - Seeking Alpha